Synapse - Hematologic Malignancies, Division of

Results (170)

Lung adenocarcinomas with mucinous histology: clinical, genomic, and immune microenvironment characterization and outcomes to immunotherapy-based treatments and KRASG12C inhibitors

Journal Article

Di Federico, A.; Hong, L.; Elkrief, A.; Thummalapalli, R.; Cooper, A. J.; Ricciuti, B.; Digumarthy, S.; Alessi, J. V.; Gogia, P.; Pecci, F.; more...
Annals of Oncology (2025)

Fulltext@MSK | Save

Clinical outcomes of patients with metastatic urothelial carcinoma (mUC) discontinuing enfortumab vedotin (EV) monotherapy (mono) without disease progression

Meeting Abstract

Sternschuss, M.; Whiting, K.; Teo, M. Y.; Bajorin, D.; Kotecha, R.; Laccetti, A. L.; Xiao, H.; Feld, E.; McHugh, D. J.; Keegan, N.; more...
Annals of Oncology (2024)

Fulltext@MSK | Save

Peripheral blood (PB) T cell phenotype and tumor microenvironment (TME) subtype are independently associated with immune checkpoint blockade (ICB) outcomes in sarcomas

Meeting Abstract

Rosenbaum, E.; Ehrich, F.; Bradic, M.; Kelly, C. M.; Movva, S.; Chan, J.; Chi, P.; Banks, L.; Dickson, M.; Keohan, M. L.; more...
Annals of Oncology (2024)

Fulltext@MSK | Save

A retrospective single-center study of outcomes to immune checkpoint blockade-based therapy in leiomyosarcoma

Meeting Abstract

Babatunde, O.; Rosenbaum, E.; Kelly, C. M.; Desir-Camille, R.; Keohan, M. L.; Banks, L.; Avutu, V.; Chan, J.; Reed, D.; Gounder, M.; more...
Annals of Oncology (2024)

Fulltext@MSK | Save

Utility of circulating tumor DNA (ctDNA) as a molecular biomarker in the phase II trial of imatinib plus binimetinib in patients with treatment-naïve, advanced gastrointestinal stromal tumor (GIST)

Meeting Abstract

Kelly, C. M.; Bradic, M.; Saunds, S.; Avutu, V.; Chan, J.; D'Angelo, S. P.; Dickson, M.; Gounder, M.; Keohan, M. L.; Movva, S.; more...
Annals of Oncology (2024)

Fulltext@MSK | Save

An open label phase IIa study evaluating the preliminary efficacy of intratumoural tigilanol tiglate (TT) in advanced and/or metastatic soft tissue sarcoma (STS)

Meeting Abstract

Bartlett, E. K.; Li, D.; Shemla, S.; Ariyan, C. E.; Dickinson, S.; Crago, A.; Li, G.; Agaram, N.; D'Angelo, S. P.; Maki, R. G.; more...
Annals of Oncology (2024)

Fulltext@MSK | Save

A phase II study of palbociclib combined with the PD-1 inhibitor retifanlimab in patients with advanced dedifferentiated liposarcoma

Meeting Abstract

Rosenbaum, E.; Qin, L. X.; Dickson, M.; Movva, S.; Kelly, C. M.; Chan, J.; Chi, P.; Banks, L.; Keohan, M. L.; Gounder, M.; more...
Annals of Oncology (2024)

Fulltext@MSK | Save

Final clinical and liquid biopsy (LBx) results of phase II trial of sacituzumab govitecan (SG) in patients (Pts) with metastatic castration resistant prostate cancer (mCRPC) progressing on androgen receptor signaling inhibitors (ARSI)

Meeting Abstract

Lang, J. M.; Tagawa, S. T.; Slovin, S.; Sperger, J. M.; Schehr, J. L.; Stahlfeld, C.; Hintz, A. M.; Emamekhoo, H.; Rathkopf, D.; Abida, W.; more...
Annals of Oncology (2024)

Fulltext@MSK | Save

Total neoadjuvant FLOT chemotherapy in oesophagogastric adenocarcinoma: An international cohort study

Meeting Abstract

Clements, H. A.; Dobrzhanskiy, O.; Yang, J.; Bausys, A.; Ferri, L. E.; Ku, G. Y.; Smyth, E. C.; Underwood, T. J.; Petty, R. D.
Annals of Oncology (2024)

Fulltext@MSK | Save

Zanidatamab + chemotherapy for first-line (1L) treatment of HER2+ advanced or metastatic gastro-oesophageal adenocarcinoma (mGEA): New and updated data from a phase II trial

Meeting Abstract

Elimova, E.; Ajani, J. A.; Burris, H. A.; Denlinger, C. S.; Iqbal, S.; Kang, Y. K.; Kim, J. H.; Lee, K. W.; Lin, B.; Mehta, R.; more...
Annals of Oncology (2024)

Fulltext@MSK | Save